Annexon (ANNX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
The annual meeting is scheduled for June 11, 2026, to be held virtually, with voting available online, by phone, or by mail.
Four key proposals are up for vote: election of two Class III directors, ratification of KPMG LLP as auditor, advisory approval of executive compensation, and an amendment to increase authorized common stock.
The board recommends voting in favor of all proposals.
Only shareholders of record as of April 13, 2026, are entitled to vote.
Voting matters and shareholder proposals
Proposal 1: Elect two Class III directors to serve until 2029.
Proposal 2: Ratify KPMG LLP as independent auditor for fiscal year ending December 31, 2026.
Proposal 3: Advisory vote on executive compensation (say-on-pay).
Proposal 4: Approve amendment to increase authorized common stock from 300,000,000 to 500,000,000 shares.
Shareholder proposals for the 2027 meeting must be submitted by December 28, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The board consists of eight members divided into three classes, with staggered three-year terms.
All directors except the CEO are considered independent under Nasdaq rules.
The roles of board chair and CEO are separated.
Four standing committees: Audit, Compensation, Nominating and Corporate Governance, and Science and Technology.
Board diversity is considered in director nominations, with 56% female employees and 24% from diverse backgrounds as of March 2026.
Latest events from Annexon
- Late-stage clinical milestones on track, with $44.1M net loss and cash runway into H2 2027.ANNX
Q1 20267 May 2026 - Vonoprument showed 73% risk reduction in vision loss for GA, with pivotal Phase 3 data due Q4 2026.ANNX
KOL event29 Apr 2026 - Late-stage C1q inhibitors show strong efficacy in GBS and GA, with pivotal data due in 2026.ANNX
Corporate presentation27 Apr 2026 - Key votes include director elections, auditor ratification, and a major share authorization increase.ANNX
Proxy filing27 Apr 2026 - Board recommends approval of all proposals, including share increase and executive compensation.ANNX
Proxy filing16 Apr 2026 - Pivotal data and regulatory filings in GBS, GA, and ANX1502 expected to drive major milestones in 2026.ANNX
25th Annual Needham Virtual Healthcare Conference15 Apr 2026 - Late-stage pipeline advances and strong cash position support multiple 2026 milestones.ANNX
Q4 202530 Mar 2026 - Late-stage neuroinflammatory pipeline poised for major clinical and commercial milestones.ANNX
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - ANX005 30 mg/kg met key efficacy and safety endpoints in GBS, advancing toward FDA submission.ANNX
Study Update31 Jan 2026